Skip to main content
. 2013 Mar 21;19(11):1811–1819. doi: 10.3748/wjg.v19.i11.1811

Table 2.

Serum α-fetoprotein level of different tumor related factors n (%)

Variables n = 2304 AFP (μg/L) P value
HBV infection < 0.001
Yes 1875 (81.4) 573.9 ± 547.7
No 429 (18.6) 398.4 ± 522.3
Tumor size(cm) < 0.001
≤ 5 871 (37.8) 444.9 ± 514.2
5-10 804 (34.9) 499.5 ± 536.4
≥ 10 629 (27.3) 808.4 ± 529.2
Tumor number 0.451
1 1666 (72.2) 531.9 ± 18.9
2 288 (12.5) 532.2 ± 44.7
≥ 3 350 (15.3) 556.0 ± 42.2
Vascular invasion < 0.001
No 1714 (74.4) 502.1 ± 543.1
Yes 590 (25.6) 694.1 ± 546.9
Tumor differentiation1 0.007
High 139 (7.5) 207.3 ± 420.8
Intermediateb 963 (52.3) 527.9 ± 538.4
Low 741 (40.2) 559.2 ± 545.7
TNM staging 0.306
I 495 (21.5) 578.6 ± 549.3
II 289 (12.5) 493.3 ± 542.2
IIIA 726 (31.5) 548.6 ± 544.3
IIIB 214 (9.3) 585.3 ± 553.4
IIIC 101 (4.3) 558.9 ± 551.7
IV 479 (20.8) 534.0 ± 545.9
BCLC staging 0.008
A 869 (37.7) 506.2 ± 537.4
B 251 (10.9) 590.1 ± 551.1
C 1028 (44.6) 607.3 ± 553.3
Dd 156 (6.8) 625.7 ± 529.8
China staging 0.386
I 137 (5.9) 487.8 ± 542.2
IIa 198 (8.6) 528.8 ± 533.9
IIb 893 (38.7) 560.8 ± 545.7
III 1076 (46.7) 527.9 ± 544.8
1

We assessed 1843/2304 patients who had underwent hepatectomy or fine needle aspiration.

b

P < 0.001 vs high and low differentiation groups.

d

P < 0.001 vs stage A and B of BCLC. AFP: α-fetoprotein; HBV: Hepatitis B virus; TNM: Tumor-node-metastasis; BCLC: The Barcelona-Clinic Liver Cancer Group.